Snakebites: a Neglected Public Health Crisis
There will be 5.5 million snakebites this year, resulting in 500,000 amputations and 150,000 deaths. Among the most affected are rural communities in low- and middle-income countries because current antivenoms are expensive, difficult to store, and must be administered in a hospital.
Current Antivenoms Aren't Good Enough
Our Solution: Broad-Spectrum EpiPen for Antivenom
$1B Spent Every Year on Snake Antivenom Worldwide
Our Customers and Traction
Since conventional antivenom is so expensive, only hospitals, governments, and nonprofits have enough money to purchase and store it. As a cheaper, shelf-stable alternative, we can sell Vipax to those organizations as well as military, first responders, state parks, schools, and outdoor guides.
Our Journey to Regulatory Approval
For antivenom, the regulatory pathway is shorter and cheaper than in other drug areas (i.e. oncology). In the best case scenario, we could have a fully developed product ready for consumers in three years. We're using Wefunder to raise part of a larger round (up to $1.2M) to complete all preclinical trials, file a first-round application to the FDA, and finish researching candidate venoms in Asia and the U.S. We've already raised $250K.
See our pitch deck for more information.